Depository Trust Company to process all U.S. trades; Investors to enjoy timely and efficient trades
TORONTO, Sept. 26, 2017 /CNW/ - Liberty Health Sciences Inc. (CSE:LHS) (OTCBB:LHSIF) ("Liberty" or the "Company") today announced a change in the company ticker on the OTC market. The previous symbol was "SCQBF" which reflected the name of the predecessor
Liberty also announced that it has obtained eligibility with the Depository Trust Company ("DTC") for its common shares. DTC is one of the world's largest securities depositories and provides electronic clearing and settlement of the securities of publicly traded companies. DTC is a member of the U.S. Federal Reserve System, and a registered clearing agency with the Securities and Exchange Commission.
"Our new company ticker and clearing agency ensure clarity and security for our growing U.S. investor base interested in the medical cannabis industry," said George Scorsis, CEO and Director of Liberty. "We always strive to offer investors valuable alternatives and DTC helps complete trades in a timely and efficient manner."
Liberty currently trades on the OTC Pink market and is expected to upgrade to the QB over the next month and to the QX shortly thereafter.
Liberty is committed to delivering high-quality, clean and safe pharmaceutical grade cannabis to American patients. For more information on Liberty please visit www.libertyhealthsciences.com
About Liberty Health Sciences Inc.Liberty Health Sciences Inc. ("Liberty") is an investor and operator in the medical cannabis market, capitalizing on new and existing opportunities in U.S. states where medical cannabis is legal. Liberty's stringent investment criteria for expansion maximizes returns to shareholders, while focusing on significant near- and mid-term opportunities. Liberty has an extensive background in highly regulated industries, with expertise in becoming a low-cost producer. Liberty leverages commercial greenhouse knowledge to deliver high-quality, clean and safe pharmaceutical grade cannabis to patients.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "believe", "plan", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, expectations related to the Company's intentions to upgrade to additional tiers of the OTC market. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in the United States generally, income tax and regulatory matters; the ability of Liberty to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
SOURCE Liberty Health Sciences Inc.
Subscribe to our Free Newsletters!
Fallopian tube cancer is a form of gynecologic cancer arising in the fallopian tubes, which are ...
Cushing syndrome is a collection of symptoms caused due to excessive amount of cortisol in the body ...
CAR T-cell therapy is a type of gene therapy where the patient's T-lymphocytes are genetically ...View All